Literature DB >> 24954901

Chromatin reader Brd4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining.

Andre Stanlie1, Ashraf S Yousif1, Hideo Akiyama2, Tasuku Honjo3, Nasim A Begum1.   

Abstract

Class switch recombination (CSR) is a B cell-specific genomic alteration induced by activation-induced cytidine deaminase (AID)-dependent DNA break at the immunoglobulin heavy-chain locus, followed by repair. Although chromatin-associated factors in promoting AID-induced DNA break have been widely reported, the involvement of chromatin adaptors at the repair phase of CSR remains unknown. Here, we show that the acetylated histone reader Brd4 is critical for nonhomologous end-joining (NHEJ) repair of AID- and I-SceI-induced DNA breaks. Brd4 was recruited to the DNA break regions, and its depletion from the chromatin caused CSR impairment without affecting the DNA break generation. Inhibition of Brd4 suppressed the accumulation of 53BP1 and uracil DNA glycosylase at the switch regions, perturbed the switch junctional microhomology, and reduced Igh/c-myc translocation. We conclude that Brd4 serves as a chromatin platform required for the recruitment of repair components during CSR and general DNA damage.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24954901     DOI: 10.1016/j.molcel.2014.05.018

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  39 in total

1.  miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.

Authors:  Yuki Takagawa; Yasuyuki Gen; Tomoki Muramatsu; Kousuke Tanimoto; Jun Inoue; Hiroyuki Harada; Johji Inazawa
Journal:  Mol Ther       Date:  2020-04-11       Impact factor: 11.454

2.  53BP1 Contributes to Igh Locus Chromatin Topology during Class Switch Recombination.

Authors:  Scott Feldman; Robert Wuerffel; Ikbel Achour; Lili Wang; Phillip B Carpenter; Amy L Kenter
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

3.  BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.

Authors:  Mengdong Ni; Jiajia Li; Haiyun Zhao; Fei Xu; Jingyi Cheng; Min Yu; Guihao Ke; Xiaohua Wu
Journal:  Oncogene       Date:  2021-03-12       Impact factor: 9.867

Review 4.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

5.  Identification of DNA cleavage- and recombination-specific hnRNP cofactors for activation-induced cytidine deaminase.

Authors:  Wenjun Hu; Nasim A Begum; Samiran Mondal; Andre Stanlie; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

6.  APE1 is dispensable for S-region cleavage but required for its repair in class switch recombination.

Authors:  Jianliang Xu; Afzal Husain; Wenjun Hu; Tasuku Honjo; Maki Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

7.  DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.

Authors:  Xin Jin; Yuqian Yan; Dejie Wang; Donglin Ding; Tao Ma; Zhenqing Ye; Rafael Jimenez; Liguo Wang; Heshui Wu; Haojie Huang
Journal:  Mol Cell       Date:  2018-07-26       Impact factor: 17.970

8.  BRD4S interacts with viral E2 protein to limit human papillomavirus late transcription.

Authors:  A Yigitliler; J Renner; C Simon; M Schneider; F Stubenrauch; T Iftner
Journal:  J Virol       Date:  2021-03-17       Impact factor: 5.103

9.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

Review 10.  Opinion: uracil DNA glycosylase (UNG) plays distinct and non-canonical roles in somatic hypermutation and class switch recombination.

Authors:  Ashraf S Yousif; Andre Stanlie; Nasim A Begum; Tasuku Honjo
Journal:  Int Immunol       Date:  2014-07-03       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.